A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

Milk fat globule membrane (MFGM) phospholipid compositions, methods of preparing and using the MFGM phospholipid compositions, liposomes comprising the MFGM phospholipid compositions, and methods of preparing and using the liposomes comprising the MFGM phospholipid compositions. In various examples, a MFGM phospholipid composition is formed by sequential supercritical carbon dioxide (SC—CO.sub.2) extraction of a milk product and extraction of the remaining milk product with a polar compound-modified SC—CO.sub.2 extraction, where the extract is the MFGM. In various examples, the MFGM is used to prepare liposomes. In various examples, the liposomes are prepared by expansion of a supercritical solution comprising the MFGM composition. In various examples, the liposomes are used to administer a cargo, such as, for example, hydrophilic compound(s), hydrophobic compound(s), amphiphilic compound(s), or the like, any one or all of which may be therapeutic agent(s), nutrient(s), bioagent(s), or the like, or any combination thereof to a subject.

A low nitrogen protein food composition Albutrix™ for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, in a treatment program comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A low nitrogen protein food composition Albutrix™ for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, in a treatment program comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

Compositions and methods for oral and/or mucosal administration of a biologically active agent are provided according to aspects of the present disclosure which include: a plurality of particles, wherein each particle has an exterior surface, the exterior surface defining a particle interior, the exterior surface having at least one type of zwitterionic polymer and/or zwitterionic copolymer disposed thereon and/or extending therefrom; and a biologically active agent disposed on the exterior surface and/or in the particle interior, wherein the biologically active agent is or includes a protein, peptide, or dietary supplement. According to particular aspects, compositions and methods for oral and/or mucosal administration of an anti diabetes biological agent, such as insulin and/or an insulin analog.

The rare non-dietary very-long-chain polyunsaturated fatty acids (VLC-PUFAs) uniquely found in retina and a few other tissues play a clinically significant role in retinal degeneration and development, but their physiological and interventional research has been hampered by scarcity of pure VLC-PUFAs. Disclosed herein are methods of making fatty acids, including VLC-PUFAs, and methods of using these fatty acids in, for example, treating eye disorders and supplementing the diet of a female subject who is pregnant, desiring to become pregnant, or lactating. Also disclosed are compositions containing fatty acids and methods of making and using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The rare non-dietary very-long-chain polyunsaturated fatty acids (VLC-PUFAs) uniquely found in retina and a few other tissues play a clinically significant role in retinal degeneration and development, but their physiological and interventional research has been hampered by scarcity of pure VLC-PUFAs. Disclosed herein are methods of making fatty acids, including VLC-PUFAs, and methods of using these fatty acids in, for example, treating eye disorders and supplementing the diet of a female subject who is pregnant, desiring to become pregnant, or lactating. Also disclosed are compositions containing fatty acids and methods of making and using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to a preterm human milk fortifier composition, more specifically to a preterm milk fortifier composition providing one or more specific nutrient in amounts that are missing in human milk of women who gave birth to a preterm infant. In particular the present invention relates to a fortifier composition designed for infants as a supplement to preterm human breast milk at the time the infant leaves the hospital (discharge) and after. The invention furthermore relates to the use of said preterm human milk fortifier composition.

The present invention relates to a preterm human milk fortifier composition, more specifically to a preterm milk fortifier composition providing one or more specific nutrient in amounts that are missing in human milk of women who gave birth to a preterm infant. In particular the present invention relates to a fortifier composition designed for infants as a supplement to preterm human breast milk at the time the infant leaves the hospital (discharge) and after. The invention furthermore relates to the use of said preterm human milk fortifier composition.

The present invention relates to a preterm human milk fortifier composition, more specifically to a preterm milk fortifier composition providing one or more specific nutrient in amounts that are missing in human milk of women who gave birth to a preterm infant. In particular the present invention relates to a fortifier composition designed for infants as a supplement to preterm human breast milk at the time the infant leaves the hospital (discharge) and after. The invention furthermore relates to the use of said preterm human milk fortifier composition.